JNJ 株価分析 — JOHNSON & JOHNSON (Healthcare >> Drug Manufacturers - General)
JNJ に関するよくある質問
JNJのPER(株価収益率)は?
JOHNSON & JOHNSON(JNJ)は現在PER 29.31倍で取引されています。
JNJのROE(自己資本利益率)は?
JOHNSON & JOHNSONのROEは24.76%です。
JNJの配当利回りは?
JOHNSON & JOHNSONの配当利回りは1.97%です。
JNJの品質スコア(Quality Score)は?
当社のAIはJNJの総合財務品質を100点中85点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
JNJは今が買い時ですか?
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
JNJはどのセクターに属しますか?
JOHNSON & JOHNSONはHealthcare >> Drug Manufacturers - Generalセクターに分類されます(NYSE市場)
JNJ AI Analysis Summary
Our AI summary for JNJ: JOHNSON & JOHNSON (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 29.31, ROE of 24.76%, a dividend yield of 1.97%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 256.35
Price
0.53
(0.21%)
Day Change
|
|
|---|
JNJ, ファンダメンタルスコアはvery good ( ファンダメンタル = 85) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEが昨年度比で低い
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
1050
|
| Magic Formula Rank by ROE |
1050
|
| Magic Formula Rank by ROIC |
1342
|
| Price | 256.35 |
| PBV / Sector |
7.26 / 2.68
|
| Earning Per Share | 8.75 |
| PE / Sector |
29.31 / 27.65
|
| PEG or PE/Growth / Sector |
N/A / 0.28
|
| Average 1M Daily Value |
1,761.97 M
GREAT
|
| Average 1W Daily Value |
1,751.55 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
58% |
| ポイントになる統計 |
|
75% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:04 |
| Symbol | JNJ |
| Name | JOHNSON & JOHNSON |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,409.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 616,500.23 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Phone: 732 524 0400
Website: https://www.jnj.com
Employees: 138,200
Description: Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google